Spondylocarpotarsal synostosis syndrome, a rare syndromic skeletal disorder characterized by disrupted vertebral segmentation with vertebral fusion, scoliosis, short stature, and carpal/tarsal synostosis, has been associated with biallelic truncating mutations in the filamin B gene or monoallelic mutations in the myosin heavy chain 3 gene. We herein report the case of a patient with a typical phenotype of spondylocarpotarsal synostosis syndrome who had a homozygous frameshift mutation in the refilin A gene (RFLNA) [c.241delC, p.(Leu81Cysfs*111)], which encodes one of the filamin-binding proteins. Refilins, filamins, and myosins play critical roles in forming perinuclear actin caps, which change the nuclear morphology during cell migration and differentiation. The present study implies that RFLNA is an additional causative gene for spondylocarpotarsal synostosis syndrome in humans and a defect in forming actin bundles and perinuclear actin caps may be a critical mechanism for the development of spondylocarpotarsal synostosis syndrome.
Introduction
Spondylocarpotarsal synostosis syndrome (SCT) (OMIM #272460) is characterized by disrupted vertebral segmentation with vertebral fusion, scoliosis, short stature, and carpal/tarsal synostosis. Mutations in filamin B (FLNB) (NM_001457) and myosin heavy chain 3 (MYH3) (NM_002470) have been identified in patients with autosomal recessive and autosomal dominant SCT, respectively [1] [2] [3] .
Mutations in FLNB cause five distinct skeletal diseases (SCT, Larsen syndrome, atelosteogenesis type I, atelosteogenesis type III, and boomerang dysplasia). Among these, only SCT is inherited in an autosomal recessive manner; the others are inherited in an autosomal dominant manner [4] . FLNB mutations have been reported in at least 16 families with SCT [5] , all of whom showed either nonsense or frameshift biallelic mutations predicted to induce premature translation termination or consecutive changes in amino acid sequences, indicating that conditions brought about by severe FLNB defects are associated with phenotypes of SCT [1, 2, 4] .
Filamins are dimeric actin-binding proteins [6] . Refilin A (RFLNA) and Refilin B (RFLNB) (also known as FAM101A and FAM101B, respectively) have been identified as vertebrate-specific short-lived filamin-binding proteins. Under TGF-β stimulation, filamins bind to RFLNs and transform their connecting actins into parallel bundle structures that accumulate each other to form perinuclear actin caps (Fig. 1a-c) . A series of the processes above is important for cell migration and differentiation leading to endochondral ossification and skeletal development [6, 7] .
We herein report the case of a Japanese boy with a typical phenotype of SCT who had a homozygous frameshift variant in RFLNA (NM_181709). We propose that RFLNA is an additional causative gene for SCT in humans.
Materials and methods

Case report
The patient was born at 34 weeks of gestation. At birth, his length was 43 cm (−0.7 SD) and his weight was 2.35 kg (+0.3 SD). An X-ray examination at the time of birth showed seemingly normal segmented vertebrae. At 1 year and 2 months of age, the patient was referred to us because of severe short stature. His height was 67.2 cm (−3.7 SD), weight 7.8 kg (−2.2 SD), and occipital frontal circumference 47 cm (+1.1 SD). He also had mild facial dysmorphic features with frontal bossing and anteverted nares. A skeletal survey showed spondylar fusion mainly affecting the posterior neural arches and to a lesser degree the vertebral bodies with mild scoliosis and carpo-tarsal synostosis (fusion of the capitate and hamate and probably that of the cuboid and lateral cuneiform) (Fig. 2) . He was diagnosed with SCT based on his characteristic skeletal features, severe short stature, and progressive clinical course. At the last examination at 2 years and 3 months of age, he was 72.4 cm tall (−4.3 SD). His motor and mental development was normal. The patient's parents were nonconsanguineous. The patient's father and elder brother were phenotypically normal, while his mother showed short stature (147 cm, -2.2 SD) without dysmorphic facial features or scoliosis.
Whole-exome sequencing
The family underwent trio whole-exome sequencing (WES). Genomic DNA extracted from peripheral blood Fig. 1 A schematic illustration of filamins and the formation of parallel actin bundles and perinuclear actin caps. a The structure of a monomeric chain of filamins. Filamin contains two calponin homology domains (CH1 and CH2) that have actin-binding affinity followed by 24 β-pleated sheet immunoglobulin (Ig)-like repeats (ellipses). The repeats are interrupted by two flexible hinge regions (H1 and H2) that allow filamins for structural flexibility. The Ig-like repeats contain another actin-binding domain (ABD), two RFLNs binding domains, and a C-terminal domain that contains a mechanosensor region (MSR) [5] . b Schematic illustration of a vertebrate filamin dimer (left) and formation of parallel actin bundles (right). Under the TGF-β stimulations, filamins bind to RFLNs and transform their connecting actin into a parallel bundle structure. During this process, MSRs release their holding mediators like SMADs to induce downstream signals. c The parallel actin bundles accumulate and produce perinuclear actin caps. These actin dynamics are necessary for cellular migration and differentiation. These figures are modified from those of Baudier et al. 6 and Khatau et al.
leukocytes was captured using Agilent SureSelect Exome Target Enrichment System v6 (Agilent Technologies, Santa Clara, CA, USA) and sequenced on a HiSeq TM 2500 (Illumina, San Diego, CA, USA) with 150 bp paired-end reads. Fastq format files were generated and aligned on the hg19/GRCh37 human reference genome sequence using the Novoalign software program (Novocraft Technologies, Kuala Lumpur, Malaysia). The Genome Analysis Toolkit (GAKT HaplotypeCaller) was used for variant calling and consequently implemented in an in-house workflow management tool [8, 9] . Single nucleotide variations and insertions/deletions were annotated using the ANNOVAR software program [10] . Then, rare and deleterious variants were filtered using a previously described method [11] . Based on this pedigree, autosomal dominant, recessive, and X-linked recessive models of inheritance were assumed for the analysis. This study was approved by the Institutional Review Board Committee at Nagasaki University Graduate School of Biomedical Sciences.
PCR-based expression analyses of RFLNA Total RNA was extracted from lymphoblastoid cell lines derived from the proband with the RFLNA mutation and the parents using the NucleoSpin RNA Plus kit (Takara, Shiga, Japan). RNA (2.0 μg) was reverse transcribed using the PrimeScript™ II 1st strand cDNA Synthesis Kit (Takara). The obtained cDNA and control genome DNA were amplified by PCR with primers for exon 2 (5′-GCATCAA GGTGAACCCGGA-3′) and the 3′ untranslated region in exon 3 (5′-GGCTGTTCTCTGCTTCAAGG-3′) for the RFLNA gene, as well as those for exon 5 (5′-GAACAAGG TTAAAGCCGAGCC-3′) and exon 6 (5′-GTGGCAGATT GACTCCTACCA-3′) for the PGK1 gene (NM_000291), which was utilized as an internal control. Subsequently, the PCR products were subjected to direct sequencing.
Results
Trio WES revealed a homozygous frameshift variant in the last exon 3 of the RFLNA gene in the patient (chr12:124 798 904C>-[GRCh37/hg19]; c.241delC [NM_181709]) (Fig. 3a) . The parents were heterozygous for the variant. The mutational analyses were not done for the phenotypically normal elder brother. This variant is predicted to cause a frameshift at codon 81 for RFLNA, skip the initial 136th termination codon, and result in the production of an additional 110 aberrant amino acids (p.(Leu81Cysfs*111)) (NP_859060). PCR-based expression and sequence analyses using cDNA derived from lymphoblastoid cell lines showed that the mutant allele was expressed in the patient (Fig. 3b) , and the mutant and the wild-type alleles were expressed in the parents with the heterozygous RFLNA variant (data not shown; Fig. 3b) [rs774972522]) was identified in the patient and the mother. The father had no deleterious variants in FLNB. The minor allele frequency of the c.4818C>G in FLNB variant in the general population was reported to be 0.27% in the 3.5 KJPN database. In silico analyses performed using PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) and MutationTaster (http://www.mutationtaster.org) predicted that this rare variant would be pathogenic. The expression analyses of the proband revealed a biallelic expression of FLNB without abnormal splicing variants or exonic deletions (data not shown).
There were no mutations in MYH3, RFLNB, or other genes known to be related to vertebral segmentation formation [12] .
Discussion
We identified a rare maternally derived missense FLNB variant (c.4818C>G, p.Ile1606Met) in the present patient with a typical phenotype of SCT. While SCT is caused by biallelic truncating mutations in FLNB [1, 2, 4], the expression analyses in this study showed a biallelic expression of FLNB, including normal transcripts of FLNB that originated from the paternal allele in the patient, indicating that the patient is certainly heterozygous for the FLNB variant. Furthermore, the FLNB variant has been identified among the general Japanese population. In addition, the mother with the same variant does not show the typical SCT phenotype. Collectively, the present data argue against any pathological role of the missense variant in the development of SCT, although the possibility that the variant might function as a susceptibility factor for the development of SCT or short stature remains tenable. Thus, a mutation(s) in a new, undiscovered gene(s) may be responsible for SCT in the patient.
In this regard, we identified a novel homozygous frameshift mutation in RFLNA in the patient, and propose the homozygous mutation of RFLNA as another genetic cause of SCT, based on the following findings. First, although mice with the single knockout of either Rflna or Rflnb (also known as Cfm2 and Cfm1, respectively) displayed wild-type phenotypes, double knockout mice manifested progressive scoliosis, kyphosis, vertebral fusions, intervertebral disc defects, and growth retardation [13] . The above phenotype is similar to that of Flnb-deficient mice and of human SCT patients, indicating that defects of RFLN families may lead to the phenotype of SCT in humans [1, 2, 4] . At this point, there is a phenotypic difference between Rflna single knockout mice and our patient with a homozygous RFLNA mutation. This may be associated with the difference of their genetic background and/or gene expression pattern [14] . Second, only a few heterozygous truncating variants and no homozygous null variants in RFLNA have been registered in ExAC database, implying that biallelic RFLNA mutations result in some pathogenic effects in humans. Third, Rflna is expressed in the vertebral primordia, vertebral bodies and carpal bones in embryonic mice and the expression is increased in prehypertrophic chondrocytes, implying the positive role of RFLNA in vertebral and carpal/tarsal bone development [15] . Fourth, a significantly decreased expression level of RFLNA has been observed in primary osteoblasts derived from the spinal vertebrae in patients with adolescent idiopathic scoliosis [16] . This result indicates that RFLNA has an important role in the normal development and growth of the vertebral column. Finally, the variant is predicted to retain the filamin-binding domains (FBDs) 1 and 2 but lose FBD3 and FBD4 (Fig. 3c) and thereby hardly form parallel actin bundles. Thus, the variant is likely a loss-of-function mutation, although the abnormal amino acid extension may result in the acquisition of some neomorphic functions. Indeed, primary rib chondrocytes from Rflna and Rflnb double knockout mice formed fewer actin bundles [13] . A biallelic Flnb defect is also predicted to affect the parallel actin bundle formation. In addition, MYH3 mutations have been reported to alter TGF-β canonical signaling [3] . Thus, a defect in forming actin bundles and perinuclear actin caps may be a critical mechanism responsible for the development of SCT. This variant is predicted to skip the initial termination, and result in the production of an additional 110 aberrant amino acids (a gray box). This mutated protein is predicted to retain the filamin-binding domains (FBDs) 1 and 2 but lose the FBD3 and FBD4 (blue boxes)
In conclusion, we propose, for the first time, an association between a homozygous mutation of RFLNA and SCT. Further studies and the accumulation of additional cases with RFLNA mutations are needed to clarify the pathogenic significance of RFLNA mutations.
